[Acupoint application for Hashimoto's thyroiditis with liver- stagnation: a randomized controlled trial].

Objective: To observe the clinical efficacy and safety of acupoint application for Hashimoto's thyroiditis (HT) with liver- stagnation.

Methods: One hundred and fifty patients of HT with liver- stagnation were randomly divided into an acupoint application group (75 cases, 11 cases were excluded, 5 cases dropped out) and a control group (75 cases, 12 cases excluded, 3 cases dropped out). Based on the health education combined with conventional western medicine treatment, the patients in the acupoint application group were treated with acupoint application, while the patients in the control group were treated with placebo acupoint application. Shenque (CV 8), bilateral Yongquan (KI 1), Yeshi, and point were selected in both groups, with Yeshi treated once a week and the remaining acupoints treated every other day, for a total of 4 weeks. The serum levels of thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH), as well as the thickness of thyroid left lobe, right lobe, and isthmus, TCM symptom score, hospital anxiety and depression scale (HADS) score, and MOS 36-item short form health survey (SF-36) score were compared between the two groups before and after treatment. Adverse reactions in both groups were observed.

Results: Compared with before treatment, in the acupoint application group, the serum levels of TgAb and TPOAb were reduced after treatment (<0.05), and the scores of role physical (RP), body pain (BP), vitality (VT), role emotional (RE), and mental health (MH) in SF-36 were increased after treatment (<0.01, <0.001). The thickness of the thyroid isthmus after treatment was smaller than that before treatment (<0.05), and the TCM symptom scores and HADS anxiety (HADS-A) scores after treatment were lower than those before treatment (<0.001, <0.01) in both groups. In the control group, the scores of physical function (PF), RP, BP, VT, and RE in SF-36 after treatment were higher than those before treatment (<0.05, <0.01, <0.001). There was no statistically significant difference in serum FT3, FT4, and TSH levels within the groups (>0.05). There was no statistically significant difference in the above indexes between the two groups (>0.05). The incidence of adverse reactions in the acupoint application group and the control group was 20.0% (15/75) and 10.7% (8/75) respectively, with skin allergy being the main adverse reaction.

Conclusion: Acupoint application could reduce the serum levels of TgAb and TPOAb in patients of HT with liver- stagnation, alleviate thyroid enlargement, improve TCM symptoms and anxiety, and improve quality of life, with safe and reliable clinical efficacy.